NCT00950430
Imaging of Brain Amyloid Plaques in the Aging Population
Enrolling by Invitation
PHASE4Ages 30+InterventionalDiagnosticMayo ClinicInvestigator-initiated
~8,000 participants
Updated 2026-06-23 on ClinicalTrials.gov
What's tested:Pittsburgh Compound B (C-11 PiB)F-18 FDGTau (18-F-AV-1451)
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
To understand the predictive ability of PiB PET imaging for neurodegenerative diseases.
Measured over up to 20 years
Conditions
Where it's being run
1 sites across 1 statesMinnesota1
Study leadership
- Val Lowe, M.D. · PRINCIPAL_INVESTIGATOR · Mayo Clinic
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Age 30-100
Subjects who have completed or are scheduled to undergo the neurological evaluation procedures in the Mayo Clinic Study of Aging, Mayo ADRC, or Mayo neurodegenerative disease clinics.
Exclusion
Subjects unable to lie down without moving for 10 minutes
Women who are pregnant or cannot stop breast feeding for 24 hours at the time of scanning
Claustrophobic patients unable to tolerate the scans
What this trial measures
- To understand the predictive ability of PiB PET imaging for neurodegenerative diseases.up to 20 years